An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)

N/ACompletedNCT01392001

Hoffmann-La Roche322 enrolled

Overview

This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with \>5 mg prednisone or equivalent for at least 3 months .

Study Type

OBSERVATIONAL

Enrollment

322

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Patients with rheumatoid arthritis for whom the rheumatologist decided to introduce RoActemra * Patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months Exclusion Criteria: * Participation in a clinical trial in rheumatoid arthritis

Locations (116)

Outcomes

Primary Outcomes

Percentage of patients receiving </= 5 mg/day prednisone (or equivalent) after 12 months of treatment with RoActemra/Actemra